News Breaks |
|
|
| February 27, 2013 |
| 11:11 EDT |  | BDBD, CWH, ENDP, AUXL, NI | High option volume stocks: BDBD CWH ENDP AUXL NI
|
|
|
News For BDBD;CWH;ENDP;AUXL;NI From The Last 14 Days Check below for free stories on BDBD;CWH;ENDP;AUXL;NI the last two weeks. |
|
|
| May 17, 2013 |
| 11:53 EDT | | ENDP | Options with decreasing implied volatility: SGMO ARNA CSC ENDP
 Subscribe for More Information |
|
| May 16, 2013 |
| 10:03 EDT |  | ENDP | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 08:27 EDT | | ENDP | Endo Health upgraded to Buy from Neutral at Buckingham
Buckingham upgraded Endo Health based on attractive risk/reward and expectations for a more detailed strategy from the new CEO, maybe by Q2 results. Price target remains $41. |
|
| May 15, 2013 |
| 12:59 EDT |  | CWH | Corvex, Related comment on result of CommonWealth annual meeting
Subscribe for More Information |
|
| 09:04 EDT | | CWH | CommonWealth says Morea failed re-election as trustee, accepts appointment
CommonWealth REIT announced the results of its annual meeting, held yesterday. Joseph Morea received less than the majority of shares required to be re-elected as an Independent Trustee. As a result, Morea resigned from the Board. "The Board determined that the insufficient vote for Mr. Morea appeared not to be directed at any personal failings of Mr. Morea, but rather to be the result of the positions taken by the Board to oppose the hostile takeover efforts being pursued by Corvex Management LP and Related Fund Management, LLC. In these circumstances, and because the Board’s determination that Mr. Morea’s continued service and leadership would be in the Trust’s best interest, the Board requested that Mr. Morea accept appointment to the vacancy created by his resignation," the company said. Morea subsequently accepted appointment as an Independent Trustee. Shareholders also approved, with 75% of all shares voted, a nonbinding, advisory proposal approving the compensation paid to CWH’s named executive officers and approved, with 81% of all shares voted, the ratification of the appointment of Ernst & Young LLP as CWH’s independent registered public accounting firm. |
|
| May 14, 2013 |
| 14:36 EDT | | NI | NiSource increases quarterly dividend 4.2%
Subscribe for More Information |
|
| May 13, 2013 |
| 09:27 EDT |  | ENDP | Endo Health downgraded to Market Perform from Outperform at William Blair
|
|
| 09:25 EDT | | ENDP | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 09:04 EDT |  | ENDP | Endo Health falls 4.8%
Endo Health is down 4.8%, or $1.67, to $33.30 |
|
| 08:13 EDT |  | ENDP | Endo Health price target lowered to $31 from $35 at Susquehanna
Subscribe for More Information |
| |
| 07:49 EDT | | ENDP | FDA decision on Opana a modest positive for Impax, says Leerink
Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires. |
|
| 07:45 EDT | | ENDP | Endo Health price target lowered to $36 from $42 at Stifel
Subscribe for More Information |
|
| 07:32 EDT | | ENDP | Endo Health downgraded to Sell from Neutral at Lazard Capital
Subscribe for More Information |
|
| 07:20 EDT | | ENDP | Endo Health price target lowered to $37 from $47 at Jefferies
Jefferies lowered its price target for Endo Health after the FDA ruled that crushable Opana generics can come to market. The firm keeps a Buy rating on the stock, saying the company's spending flexibility is underappreciated. |
|
| 06:48 EDT | | ENDP | Endo Health downgraded to Fair Value from Buy at CRT Capital
Subscribe for More Information |
|
| May 10, 2013 |
| 16:59 EDT | | ENDP | Endo Health says FDA denial could cut FY13 adjusted EPS by 55c
Subscribe for More Information |
|
| 15:45 EDT | | ENDP | Endo Health trading halted, pending news
|
|
| 15:44 EDT | | ENDP | Endo Health denied petition to block Opana ER generics
Subscribe for More Information |
|
| May 9, 2013 |
| 16:52 EDT | | ENDP | BDSI's Phase 3 trials for BEMA Buprenorphine to finish late 2013 or early 2014
Subscribe for More Information |
|
| 16:44 EDT | | ENDP | Blue Ridge Capital reports 5.98% passive stake in Endo Health
Subscribe for More Information |
| |
|
|
|
|
